PremiumRatingsPromising Long-Term Data and Strategic Advancements Position Viridian Therapeutics for Growth Viridian Reports Positive Phase 3 Trial Results Viridian Therapeutics announces long-term durability data from THRIVE trial PremiumRatingsViridian Therapeutics: Hold Rating Amid Limited Near-Term Catalysts and Awaited 2026 Data Viridian Therapeutics price target lowered to $38 from $42 at Citizens JMP Viridian Therapeutics Reports Q1 2025 Progress and Financials PremiumRatingsBuy Rating for Viridian Therapeutics Driven by Promising Pipeline and Strategic Positioning in Thyroid Eye Disease Market Viridian Therapeutics Appoints Jeff Ajer to Board Viridian Therapeutics appoints Ajer to its board of directors 
